Title:
PYRAZOLE DERIVATIVES
Document Type and Number:
WIPO Patent Application WO/2017/117708
Kind Code:
A1
Abstract:
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
Inventors:
CHEN LI (CN)
JIN XIAOWEI (CN)
JIN XIAOWEI (CN)
Application Number:
PCT/CN2016/070115
Publication Date:
July 13, 2017
Filing Date:
January 05, 2016
Export Citation:
Assignee:
HUA MEDICINE (SHANGHAI) LTD (CN)
International Classes:
A61K31/397; C07D401/06; A61P25/00; A61P29/00; C07D205/04; C07D207/10
Foreign References:
| CN105121424A | 2015-12-02 |
Other References:
EGLE ARBACIAUSKIENE ET AL.: "Pd-catalyzed cross-coupling reactions of halogenated 1- phenylpyrazol-3-ols and related triflates", TETRAHEDRON, vol. 65, no. 37, 9 July 2009 (2009-07-09), pages 7817 - 7824, XP055288662
SHIGEMOTO, R.NOMURA, S.HIDEMITSU, S. ET AL., NEUROSCIENCE LETT, vol. 163, 1993, pages 53 - 57
GASPARINI, F.BILBE, G.GOMEZ-MANCILLA, G.SPOOREN, W., CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 11, no. 5, 2008, pages 655 - 665
ROCHER, J.-P.BONNET, B.BOLEA, C. ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 11, 2011, pages 680 - 695
DEKUNDY, A.GRAVIUS, A.HECHENBERGER, M ET AL., J. NEURAL TRANSM., vol. 118, 2011, pages 1703 - 1716
NISWENDER, C. M.CONN, P. J., ANNU REV PHARMACOL TOXICOL., vol. 50, 2010, pages 295 - 322
EMMITTE KA.: "mGluR5 negative allosteric modulators, a patent review (2010-2012", EXPERT OPIN THER PAT., vol. 23, no. 4, April 2013 (2013-04-01), pages 393 - 408, XP055615303, DOI: 10.1517/13543776.2013.760544
GUIYING LIMORTEN J RGENSENBRIAN M CAMPBELL: "Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013", PHARMACEUTICAL PATENT ANALYST., vol. 2, no. 6, pages 767 - 802
SHIGEMOTO, R.NOMURA, S.HIDEMITSU, S. ET AL., NEUROSCIENCE LETT, vol. 163, 1993, pages 53 - 57
GASPARINI, F.BILBE, G.GOMEZ-MANCILLA, G.SPOOREN, W., CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 11, no. 5, 2008, pages 655 - 665
ROCHER, J.-P.BONNET, B.BOLEA, C. ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 11, 2011, pages 680 - 695
DEKUNDY, A.GRAVIUS, A.HECHENBERGER, M ET AL., J. NEURAL TRANSM., vol. 118, 2011, pages 1703 - 1716
NISWENDER, C. M.CONN, P. J., ANNU REV PHARMACOL TOXICOL., vol. 50, 2010, pages 295 - 322
EMMITTE KA.: "mGluR5 negative allosteric modulators, a patent review (2010-2012", EXPERT OPIN THER PAT., vol. 23, no. 4, April 2013 (2013-04-01), pages 393 - 408, XP055615303, DOI: 10.1517/13543776.2013.760544
GUIYING LIMORTEN J RGENSENBRIAN M CAMPBELL: "Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013", PHARMACEUTICAL PATENT ANALYST., vol. 2, no. 6, pages 767 - 802
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: